Patent: 9,951,010
✉ Email this page to a colleague
Summary for Patent: 9,951,010
Title: | Compounds as CRTH2 antagonist and uses thereof |
Abstract: | The compounds of Formula (I) which can be used as CRTH2 receptor antagonists are provided. The compounds of Formula (I) can be used in the treatment and prevention of asthma, allergic rhinitis and atopic dermatitis, as well as other diseases mediated by prostaglandin D2 (PGD2) at the CRTH2 receptor. ##STR00001## |
Inventor(s): | Zhang; Yingjun (Dongguan, CN), Yu; Tianzhu (Dongguan, CN), Liu; Bing (Dongguan, CN), Zhang; Xiangyu (Dongguan, CN), Zhang; Shiguo (Dongguan, CN), Cheng; Changchung (Dongguan, CN), Zhang; Jiancun (Dongguan, CN) |
Assignee: | SUNSHINE LAKE PHARMA CO., LTD. (Dongguan, Guangdong, CN) |
Application Number: | 15/504,018 |
Patent Claims: | see list of patent claims |
Details for Patent 9,951,010
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | XOLAIR | omalizumab | For Injection | 103976 | 06/20/2003 | ⤷ Try a Trial | 2034-09-13 |
Genentech, Inc. | XOLAIR | omalizumab | Injection | 103976 | 09/28/2018 | ⤷ Try a Trial | 2034-09-13 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |